CRMD Key Statistics, Chart & Performance
The current stock price of CRMD is 11.21 USD. In the past month the price increased by 2.5%. In the past year, price increased by 37.11%.
CRMD Latest News, Press Relases and Analysis
CRMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.97 | 997.32B | ||
| JNJ | JOHNSON & JOHNSON | 20.61 | 515.53B | ||
| MRK | MERCK & CO. INC. | 11.45 | 250.31B | ||
| PFE | PFIZER INC | 8.21 | 149.45B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.21 | 109.68B | ||
| ZTS | ZOETIS INC | 19.07 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.35 | 22.19B | ||
| VTRS | VIATRIS INC | 5.06 | 13.57B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.49 | 10.73B | ||
| CORT | CORCEPT THERAPEUTICS INC | 100.23 | 9.28B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.00B |
Related stock screener links
About CRMD
Company Profile
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Company Info
CORMEDIX INC
300 Connell Drive, Suite 4200
Berkeley Heights NEW JERSEY 07922 US
CEO: Khoso Baluch
Employees: 64
Phone: 19085179500
CORMEDIX INC / CRMD FAQ
What does CRMD do?
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
What is the stock price of CORMEDIX INC today?
The current stock price of CRMD is 11.21 USD. The price decreased by -2.44% in the last trading session.
What is the dividend status of CORMEDIX INC?
CRMD does not pay a dividend.
How is the ChartMill rating for CORMEDIX INC?
CRMD has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is CRMD stock listed?
CRMD stock is listed on the Nasdaq exchange.
Is CORMEDIX INC (CRMD) expected to grow?
The Revenue of CORMEDIX INC (CRMD) is expected to grow by 684.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of CRMD stock?
CORMEDIX INC (CRMD) has a market capitalization of 883.24M USD. This makes CRMD a Small Cap stock.
CRMD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CRMD. When comparing the yearly performance of all stocks, CRMD is one of the better performing stocks in the market, outperforming 78.01% of all stocks.
CRMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CRMD. CRMD has only an average score on both its financial health and profitability.
CRMD Financial Highlights
Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 2.06. The EPS increased by 354.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 75.83% | ||
| ROA | 21.64% | ||
| ROE | 43.43% | ||
| Debt/Equity | 0.39 |
CRMD Forecast & Estimates
13 analysts have analysed CRMD and the average price target is 19.38 USD. This implies a price increase of 72.88% is expected in the next year compared to the current price of 11.21.
For the next year, analysts expect an EPS growth of 858.16% and a revenue growth 684.25% for CRMD